INTI Projected Dividend Yield

Inhibitor Therapeutics Inc ( OTCBB : INTI )

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. Co. is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the U.S. utilizing itraconazole, a drug approved by the U.S. Food and Drug Administration (FDA) to treat fungal infections. Co. has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.

21 YEAR PERFORMANCE RESULTS